The product called Octaplex, currently under review by the Food and Drug Administration, would reverse the effects of warfarin — an oral drug that reduces blood clotting — in cases of major bleeding.

“Octapharma has been committed to improving the lives of people with Haemophilia A since 1983. We are glad to continue our donation initiatives, providing access to patients with haemophilia in ...

PARAMUS, N.J., Sept. 6, 2023 /PRNewswire/ -- Octapharma USA will be presented with the Research & Development Award for Outstanding Innovation in Myositis Research during the Heroes in the Fight ...

More than 2.4 million people in the United States use warfarin to keep their blood from clotting after a heart attack, stroke or other serious thromboembolic complication. But using a blood thinner ...

LACHEN, Switzerland--(BUSINESS WIRE)--Commenting on the Group’s results, Octapharma CEO and Chairman Wolfgang Marguerre said: “In 2018, we continued to drive growth in many of our products. I am ...

PARAMUS, N.J. (December 2, 2020) - Clinical research presented by Octapharma USA at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition will highlight the investigational use ...

FVIII inhibitor development is the most serious treatment complication in previously untreated patients (PUPs) with severe haemophilia A. The development of inhibitors against exogenous FVIII can ...

PARAMUS, N.J., May 28, 2025 /PRNewswire/ -- Octapharma has released the results from its prospective, randomized, double-blind, parallel group, crossover, placebo-controlled phase 3 study comparing ...

LACHEN, Switzerland, June 10, 2024 /PRNewswire/ -- The most recent developments from Octapharma's Haematology portfolio will be presented at the 32 nd Congress of the International Society on ...

LACHEN, Switzerland, Nov. 27, 2023 /PRNewswire/ -- New clinical data from Octapharma's haematology portfolio will be presented during the scientific program at the 65th American Society of Hematology ...